- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01307384
Zimmer Continuum Metal em Polietileno (MoP) Estudo de acompanhamento clínico pós-mercado (PMCF)
Estudo prospectivo de acompanhamento clínico pós-comercialização do metal contínuo no sistema acetabular de polietileno
This is a prospective, multi-center, non-randomized, non-controlled study designed to obtain survival and outcome data on the Continuum Metal on Polyethylene Acetabular System when used in primary total hip arthroplasty.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The safety and performance of the Continuum Metal on Polyethylene Acetabular System will be confirmed by the assessment of survival and outcome data. Assessments will include standard scoring systems, radiographs and adverse event records. Data will be used to monitor pain, mobility, and survivorship of the Continuum Metal on Polyethylene Acetabular system in primary total hip arthroplasty. Metal ion (cobalt, chromium and titanium) and renal function (BUN, Creatinine and GFR) levels will be analyzed for a subset of the enrolled study subjects.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
California
-
Fremont, California, Estados Unidos, 94538
- Sah Orthopaedic Associates
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80204
- Denver Health Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Patients from surgeons medical practice who are candidates for primary hip arthroplasty.
The study population will be comprised of 300 males and females who require primary total hip arthroplasty. Subjects will be enrolled at up to 7 clinical sites. Subjects must be geographically accessible throughout the study and be willing and able to attend required follow-up appointments. Candidates who express interest in study participation will be offered informed consent, and eligibility will be determined based upon the inclusion/exclusion criteria.
Descrição
Inclusion Criteria
-
Patient is 18 to 75 years of age, inclusive.
-
Patient is skeletally mature.
-
Patient qualifies for primary unilateral or bilateral (simultaneous or staged) total hip arthroplasty (THA) based on physical exam and medical history including the following:
- Avascular necrosis (AVN)
- Osteoarthritis
- Inflammatory arthritis (i.e., Rheumatoid arthritis)
- Post-traumatic arthritis
-
Patient has no history of previous prosthetic replacement device of any type, including surface replacement arthroplasty, endoprosthesis, etc. of the affected hip joint(s).
-
Patient has moderate, marked or disabling pain.
-
Patient is willing and able to provide written informed consent.
-
Patient is willing and able to cooperate in the required post-operative therapy.
-
Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.
-
Patient has participated in the Informed Consent process and has signed the IRB approved informed consent.
Exclusion Criteria:
-
The patient is:
- A prisoner
- Mentally incompetent or unable to understand what participation in the study entails
- A known alcohol or drug abuser
- Anticipated to be non-compliant
-
The patient has a neuromuscular disorder, vascular disorder or other conditions that could contribute to prosthesis instability, prosthesis fixation failure or complications in postoperative care.
-
The patient has a neurologic condition in the ipsilateral or contralateral limb which affects lower limb function.
-
The patient has a diagnosed systemic disease that could affect his/her safety or the study outcome.
-
The patient is known to be pregnant.
-
The patient is unwilling or unable to give consent or to comply with the follow-up program.
-
The patient has received an investigational drug or device within the previous 6 months.
-
The patient has an active or latent infection in or about the affected hip joint or an infection distant from the hip joint that may spread to the hip hematogenously.
-
The patient has insufficient bone stock to fix the component. Insufficient bone stock exists in the presence of metabolic bone disease (i.e., osteoporosis), cancer, and radiation. Note: Dual Energy X-ray Absorptiometry (DEXA) may be used to assess the presence of adequate bone stock.
-
The patient has osteoradionecrosis in the affected hip joint.
-
The patient has a known sensitivity or allergic reaction to one or more of the implanted materials.
-
The patient has known local bone tumors and/or cysts in the operative hip.
-
The patient has a Body Mass Index (BMI) > 40.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Continuum Acetabular System
Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System |
Used in primary hip arthroplasty
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Survivorship
Prazo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Based on removal or intended removal of the device and determined using the Kaplan-Meier method. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Safety / Adverse Events
Prazo: Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Safety will be evaluated by monitoring the frequency and incidence of device related adverse events or unanticipated adverse device effects in investigational subjects. |
Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pain and Function / HHS
Prazo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Pain and function will be measured using the Harris Hip Score self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Pain and Function / OHS
Prazo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Pain and function will be measured using the Oxford Hip Score self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Health Status / SF-12
Prazo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Health status will be measured using the SF-12 self assessment. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
|
Health Status / Radiographic Parameters
Prazo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
X-rays will be evaluated for acetabular cup angle, acetabular cup migration, femoral stem position, femoral stem subsidence and femoral stem shift. |
6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Metal Ion / Cobalt
Prazo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Metal Ion / Chromium
Prazo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Metal Ion / Titanium
Prazo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / BUN
Prazo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / Creatinine
Prazo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
|
Renal Function / GFR
Prazo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range. |
Pre-operatively and at 6 months, 1 year, 2 year and 5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Hillary Overholser, Zimmer Biomet
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças ósseas
- Doenças musculoesqueléticas
- Processos Patológicos
- Doenças articulares
- Doenças Reumáticas
- Doenças do Tecido Conjuntivo
- Doenças autoimunes
- Doenças do sistema imunológico
- Necrose
- Condições Patológicas, Sinais e Sintomas
- Doenças da Pele e do Tecido Conjuntivo
- Artrite
- Osteoartrite
- Artrite, Reumatóide
- Osteonecrose
- Procedimentos cirúrgicos, operatórios
- Artroplastia, substituição
- Artroplastia
- Procedimentos ortopédicos
- Procedimentos de cirurgia plástica
- Implante de prótese
- Artroplastia, substituição, quadril
Outros números de identificação do estudo
- CMU2010-02H
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .